The Watchlist Series | Regeneron Comes Through on Promise & Initiates Investigation of REGN-COV2

Watchlist TrialSite News
Regeneron has received $450 million for an advanced investigational monoclonal antibody targeting COVID-19 called REG-COV2. According to the company’s public-facing statements, the two antibodies identified represented the most potent, non-competing and virus-neutralizing antibodies and have scaled them up for clinical use with the company’s in-house VelociMab and manufacturing infrastructure. The two antibodies bind non-competitively to the critical receptor binding domain (RBD) of the virus’s spike protein, which diminishes the ability of mutant viruses to escape treatment, as the company demonstrates in upcoming Science publications of preclinical research.